2025-10-04 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data provided, formatted for a concise English report.

## Recursion Pharmaceuticals Inc. (RXRX) Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return Difference:** RXRX underperformed the S&P 500 by -52.85% (RXRX: -12.36%, VOO: 40.49%).
*   **Relative Divergence:** 8.1 (indicating RXRX is near the lower end of its historical performance range relative to VOO).

**Analysis of Alpha, Beta, CAGR, and MDD:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2021-2023  | 22.0%   | 81.0%   | 26.0%  | -0.2  | 4.3    |
| 2022-2024  | 11.0%   | 81.0%   | -10.0% | 0.1   | 3.0    |
| 2023-2025  | 30.0%   | 80.0%   | -33.0% | 0.1   | 2.4    |

*   **CAGR:** Volatile, ranging from 11% to 30%, indicating inconsistent growth.
*   **MDD:** Consistently high (around 80%), suggesting significant risk and price volatility.
*   **Alpha:** Fluctuates significantly (26% to -33%), implying RXRX's performance is heavily influenced by factors beyond the market. Negative alpha in recent periods (2022-2025) is a red flag.
*   **Beta:** Low (around 0.1), indicating RXRX's price movements are relatively independent of the broader market (S&P 500).  The initial negative beta might be an anomaly.
*   **Cap(B):** Market cap decreasing from 4.3B to 2.4B

**2. Recent Stock Price Movement**

*   **Current Price:** $5.49
*   **Last Market Activity:** Price decreased slightly (-0.54%) compared to the previous close.
*   **Moving Averages:**
    *   5-day MA: 5.164
    *   20-day MA: 4.8857
    *   60-day MA: 5.2507

**Analysis:** The stock price is trading above its 5-day, 20-day, and 60-day moving averages, suggesting a potential short-term upward trend. The slight price decrease in the last market activity is negligible.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment)
*   **RSI:** 70.11 (Overbought)
*   **PPO:** 1.93
*   **Hybrid Signal:**  Buy 100% of cash (195 shares) with a small monthly investment.
*   **Recent (20-day) Relative Divergence Change:** +8.1 (Short-term increase)
*   **Expected Return:** -49.2% (Long-term underperformance vs. S&P 500)

**Analysis:** The MRI suggests a medium level of investment risk.  The RSI indicates the stock is currently overbought, which might suggest a potential pullback. The hybrid signal suggests buying the stock with a small amount of cash. The recent increase in relative divergence suggests positive short-term momentum. However, the negative expected return highlights significant concerns about RXRX's long-term performance relative to the market. The price change of -0.54% is not significant enough to indicate a major volatility event.

**4. Recent News & Significant Events**

*   **Positive News:** Several articles highlight a recent rally in RXRX stock, potentially driven by renewed interest in biotech AI initiatives and a "Buy" reiteration from Needham.
*   **Mixed/Cautionary News:** Jim Cramer expressed the need for a "proof of concept," and other articles question the long-term potential and riskiness of the stock.

**Analysis:** The news sentiment is mixed. While there's short-term excitement due to recent gains, concerns remain about the company's ability to demonstrate tangible results and long-term viability.

**4-2. Analyst Opinions**

*   **Consensus:** No Key rating given, 6 Analyst Opinions
*   **Target Price:** Average: $6.47, High: $10.00, Low: $3.00

**Analysis:** The analyst opinions are mixed with a considerable spread between the high and low target prices, indicating uncertainty about RXRX's future value.

**5. Recent Earnings Analysis**

| Date       | EPS    | Revenue   |
|------------|--------|-----------|
| 2025-08-05 | -0.41  | 0.02 B$   |
| 2025-05-05 | -0.5   | 0.01 B$   |
| 2024-11-06 | -0.34  | 0.03 B$   |
| 2024-08-08 | -0.4   | 0.01 B$   |
| 2025-08-05 | -0.4   | 0.01 B$   |

**Analysis:** RXRX consistently reports negative earnings per share (EPS), indicating a lack of profitability.  Revenue is relatively low and fluctuates.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |

Capital and Profitability:

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $0.92B    | -18.70%   |
| 2025-03-31 | $0.93B    | -21.68%   |
| 2024-12-31 | $1.03B    | -17.29%   |
| 2024-09-30 | $0.52B    | -18.27%   |
| 2024-06-30 | $0.58B    | -16.69%   |

**Analysis:**

*   **Revenue:** Low and inconsistent.
*   **Profit Margin:** Generally negative, with some positive quarters. This indicates that while they may generate some profit in certain quarters, they are generally operating at a loss.
*   **Equity:** Fluctuating equity levels.
*   **ROE:** Negative return on equity, reflecting the company's inability to generate profits from shareholder investments.

**7. Overall Summary & Conclusion**

RXRX is a high-risk, high-potential biotech company with significant challenges.

*   **Strengths:** Recent positive stock momentum and analyst "Buy" ratings suggest short-term potential.  The company operates in a high-growth sector (AI-driven drug discovery).
*   **Weaknesses:** Consistent unprofitability, underperformance relative to the S&P 500, high volatility, and negative long-term expected return. The need for "proof of concept" highlighted by analysts is a major concern.
*   **Recommendation:** RXRX is suitable only for investors with a high-risk tolerance and a long-term investment horizon.  The company needs to demonstrate tangible results to justify its current valuation.  A careful evaluation of future earnings reports and clinical trial data is crucial before considering a significant investment.

